Rhythm Pharmaceuticals
RYTM
78 hedge funds and large institutions have $908M invested in Rhythm Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 38 increasing their positions, 21 reducing their positions, and 17 closing their positions.
81% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 21
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
2.51% less ownership
Funds ownership: 93.63% → 91.11% (-2.5%)
6% less capital invested
Capital invested by funds: $970M → $908M (-$61.6M)
8% less funds holding
Funds holding: 85 → 78 (-7)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$24M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$17.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.2M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.9M |
| 5 |
BlackRock
New York
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$32.3M |
| 2 |
TG
TRV GP
Boston,
Massachusetts
|
-$31.6M |
| 3 |
DM
Deerfield Management
New York
|
-$10.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.35M |
| 5 |
PA
Perceptive Advisors
New York
|
-$4.31M |
RYTM Hedge Fund Activity: Q3 2018 in Review
78 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q3 2018, worth a combined $908M — down 6.3% from $970M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RYTM and 10 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 38 added.
The largest buyer was Janus Henderson Group, adding an estimated $24M. The largest seller was OrbiMed, cutting an estimated $32.3M.
- 78 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q3 2018, down from 85 in Q2 2018.
- Funds reported $908M of Rhythm Pharmaceuticals stock for Q3 2018, down 6.3% quarter-over-quarter.
- 10 funds opened new Rhythm Pharmaceuticals positions in Q3 2018 and 17 closed out, a net change of -7 holders.
- The largest Rhythm Pharmaceuticals buyer in Q3 2018 was Janus Henderson Group, an estimated $24M added.
- The largest Rhythm Pharmaceuticals seller in Q3 2018 was OrbiMed, an estimated $32.3M sold.
Based on aggregated 13F filings for Q3 2018.